articleJournal of HepatologyApr 11, 2025Closed access

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

LRLorenza RimassaSLStephen L. ChanBSBruno SangroGLGeorge LauMKMasatoshi Kudo

Humanitas University · IRCCS Humanitas Research Hospital · +35 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

94
total citations
FWCI
73.79
Percentile
100%
References
41
Citations per year

Authors

27

Topics & keywords

Topics
Keywords
  • Durvalumab
  • Tremelimumab
  • Medicine
  • Oncology
  • Internal medicine
  • Cancer
  • Immunotherapy
  • Nivolumab
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.